<DOC>
	<DOC>NCT02291549</DOC>
	<brief_summary>The RESOLVE II Study is a randomized, single-blind, parallel arm, concurrently controlled, multicenter study with 300 chronic sinusitis patients who had prior endoscopic sinus surgery but present with recurrent sinus obstruction.</brief_summary>
	<brief_title>Clinical Evaluation of Safety and Efficacy of S8 Sinus Implant in Chronic Sinusitis Patients</brief_title>
	<detailed_description>The RESOLVE II Study is a randomized, single-blind, parallel arm, concurrently controlled, multicenter trial conducted in up to 45 clinical centers (academic and private) across the United States in 300 adults with chronic sinusitis, who are indicated for revision surgery because of recurring nasal obstruction/congestion symptoms and bilateral ethmoid polyposis.</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Key inclusion criteria: Confirmed diagnosis of chronic sinusitis Previous endoscopic sinus surgery (ESS) including bilateral total ethmoidectomy Nasal obstruction/congestion symptoms despite use of intranasal steroid irrigations or sprays Indication for repeat ESS: Complaints of at least 2 symptoms of chronic sinusitis: nasal obstruction/congestion, postnasal discharge, thick nasal discharge, facial pain/pressure, or decreased sense of smell Endoscopic evidence of bilateral sinus obstruction due to polyposis (minimum grade 2 on each side) History of highdose steroid use and/or sinus steroid irrigations within the preceding 1 year Key exclusion criteria: Patient has presence of polyposis grade 1, 1.5 or 4 on either side Patient has presence of adhesions/synechiae grades 3 or 4 Patient has known history of immune deficiency Patient has concurrent condition such as cancer or HIV requiring active chemotherapy and/or immunotherapy management for the disease Patient has oralsteroid dependent condition such as COPD, asthma or other condition Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate Patient has presence of physical obstruction that would preclude access to either ethmoid sinus for implant delivery (e.g., severe septal deviation, septal spur, very small middle meatus, total obstruction of the nasal passage with severe scarring, polyposis) Patient has clinical evidence of acute bacterial sinusitis Patient has clinical evidence or suspicion of invasive fungal sinusitis Patient has evidence of disease or condition expected to compromise survival or ability to complete followup assessments during the 90day followup period Patient is currently participating in another clinical trial or has already participated in this clinical trial Patient has history of insulin dependent diabetes mellitus Patient has previously undergone ESS and experienced a cerebrospinal fluid (CSF) leak or has residual compromised vision as a result of a complication in a prior ESS procedure Patient has known dehiscence of the lamina papyracea Patient has evidence of active viral illness Patient has known history or diagnosis of glaucoma or ocular hypertension (prior ocular exam with IOP&gt;21 mm Hg and pressure lowering medication given) or posterior subcapsular cataract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>